Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

Target	VHL
Reactivity	Human, Mouse
Host	Rabbit
Clonality	Polyclonal
Tested Applications	WB, IHC, IF/ICC, FCM
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Immunogen	KLH-conjugated synthetic peptide between 43-71 amino acids from the N-terminal region of human VHL.
Purification	Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Isotype	IgG
Conjugation	Unconjugated
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Swiss Prot	P40337
NCBI Accession	NP_000542.1 NP_937799.1
Buffer	PBS containing 0.09% sodium azide.
UNSPSC Code	12352203
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.